Kyle Misewich

Recent representative transactions include assisting:

M&A and Reorganizations

• Neovasc in connection with its acquisition by Shockwave for approximately US$100-million

• NioCorp Developments Ltd. on its business combination with GX Acquisition Corp. II, a US special purpose acquisition corporation (SPAC), and concurrent financings valued at up to US$71.9-million

• Trilogy International Partners in connection with the sale of its subsidiary, Two Degrees, for NZ$1.315-billion

• Trillium Therapeutics Inc. in connection with its acquisition by Pfizer for US$2.22-billion

• Absolute Software Corporation in connection with its US$340-million acquisition of NetMotion Software, Inc.

• CRH Medical Corporation in connection with its acquisition by Well Health Technologies Corp. in a deal valued at US$372.9-million

• Novoheart Holdings Inc. in a going private transaction valued at approximately C$100-million

• Atico Mining Corporation in connection with its acquisition of Toachi Mining Inc.

• Washington Companies in connection with its C$1.5-billion acquisition of Dominion Diamond Corporation

• Trilogy International Partners on a US$875-million business combination with Alignvest Acquisition Corporation, a special purpose acquisition corporation (SPAC)

• Neovasc in connection with the sale of its tissue business and concurrent private placement to Boston Scientific for US$75-million

• Reservoir Minerals Inc. on its private placement, credit agreement and plan of arrangement with Nevsun Resources Ltd. for a total of US$575-million

• Capstone Mining in connection with its acquisition of the Pinto Valley Mine from BHP Billiton for US$650-million

• Lithium One Inc. in connection with its acquisition by Galaxy Resources for C$112-million in exchangeable shares

Corporate Finance

• The underwriters in separate public offerings of CubicFarm Systems Corp. for gross proceeds of C$20-million, C$25.3-million, C$16.2-million and C$2.8-million

• The underwriters in connection with a US$20-million public offering of units by Medicenna Therapeutics

• NervGen Pharma in connection with its US$15.23-million private placement of units

• ESSA Pharma Inc. in connection with its US$130-million underwritten public offering of common shares

• Kadestone Capital Corp. on its formation and initial public offering

• The underwriters in a C$23-million bought deal public offering of units of Rubicon Organics Inc.

• Neovasc in connection with its US$72-million MJDS registered direct offering of common shares

• Svante Technologies Inc. in connection with its US$16-million series C preferred share financing, US$100-million series D preferred share financing and US$318-million series E preferred share financing

• ESSA Pharma in connection with its US$26-million prospectus offering and concurrent private placement of common shares and pre-funded warrants

• Neovasc in connection with its US$37.5-million underwritten offering of series A and series B units (comprised of a combination of common shares or series D pre-funded warrants, series C units and series A, B, C and F warrants to purchase common shares) and concurrent US$27.8-million private placement of notes and series E warrants to purchase common shares

• The underwriters of B2Gold Corp. on its at-the-market offering of up to US$100-million

• The underwriters on a private placement of flow-through common shares of Sabina Gold & Silver Corp. for gross proceeds of approximately C$34.5-million

• Esperanza Resources Corp. on a private placement of special warrants for gross proceeds of approximately C$34-million

• NovaGold Resources Inc. on a public offering of common shares for gross proceeds of approximately US$332.5-million

Kyle is a member of The Law Society of British Columbia and the Canadian Bar Association.

Admitted to the British Columbia Bar – 2011
JD, University of Victoria – 2010
BBA (Hon.), Simon Fraser University – 2007